{{Rsnum
|rsid=12644671
|Chromosome=4
|position=34022455
|Orientation=plus
|GMAF=0.2635
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;G)
| geno3=(G;G)
| CEU | 78.8 | 18.6 | 2.7
| HCB | 54.0 | 38.7 | 7.3
| JPT | 54.0 | 38.9 | 7.1
| YRI | 26.5 | 39.5 | 34.0
| ASW | 42.1 | 47.4 | 10.5
| CHB | 54.0 | 38.7 | 7.3
| CHD | 55.0 | 35.8 | 9.2
| GIH | 70.0 | 26.0 | 4.0
| LWK | 23.6 | 44.5 | 31.8
| MEX | 62.1 | 34.5 | 3.4
| MKK | 30.8 | 50.6 | 18.6
| TSI | 80.4 | 17.6 | 2.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs12644671
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: G, MAF= 0.16, combined P value= 1.13E-04. It is also associated with etoposide clearance.
|Drugs=etoposide
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470188
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs12644671
|overall_frequency_n=31
|overall_frequency_d=128
|overall_frequency=0.242188
|n_genomes=24
|n_genomes_annotated=0
|n_haplomes=29
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}